# SELLAS Life Sciences Group, Inc. (SLS) Stock Price, News & Catalysts
Canonical URL: https://biopharmsignal.com/company/SLS
## Company Profile
- Ticker: SLS
- Exchange: NASDAQ
- Sector: Life Science Tools
- Location: United States
- Tags: Life Science Tools, Immunotherapy, Oncology
## Stock Data
- Close: 13.86 USD
- Market cap: 1549651341.42 USD
- Last updated: 2026-09-04
## Business Overview
### Late-Stage Oncology Company
SELLAS Life Sciences develops therapies for hematologic malignancies and solid tumors. Its pipeline combines a WT1-targeted immunotherapy with a differentiated small-molecule CDK9 inhibitor.
### Galinpepimut-S
Galinpepimut-S, or GPS, is a WT1-targeting immunotherapy licensed from Memorial Sloan Kettering Cancer Center. WT1 is expressed across multiple blood cancers and solid tumors, creating potential for both monotherapy and combination development.
### REGAL Phase 3 Program
The Phase 3 REGAL trial evaluates GPS as maintenance therapy in acute myeloid leukemia patients who achieved complete remission after second-line salvage treatment. The event-driven study will proceed to final analysis after the prespecified 80th event.
### SLS009
SLS009, also known as tambiciclib, is a selective CDK9 inhibitor designed to combine antitumor potency with reduced toxicity. SELLAS is evaluating the candidate in newly diagnosed frontline AML and preparing for potential clinical development in pancreatic cancer.
## Why The Stock Is Moving

As of Sep 4, 2026, SLS closed up 1.17% at $13.86. No new same-company headline was identified in the current news window.

## Future Catalysts

- The prespecified 80th event in the Phase 3 REGAL study, triggering database lock, final analysis, and subsequent topline results.
- Topline data from the Phase 2 study of SLS009 in newly diagnosed frontline AML in the fourth quarter of 2026.

## Recent News
- 2026-08-11 20:05 EST — [SELLAS Life Sciences Reports Second Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-second-quarter-2026-financial-results-and-provides--c92543e8) — Source: SELLAS Life Sciences Group, Inc.
- 2026-05-14 12:00 EST — [SELLAS Life Sciences to Participate in Upcoming Investor Conferences](https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-participate-in-upcoming-investor-conferences) — Source: SELLAS Life Sciences Group, Inc.
- 2026-05-12 20:05 EST — [SELLAS Life Sciences Reports First Quarter 2026 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-first-quarter-2026-financial-results-and-provides-corporate-update) — Source: SELLAS Life Sciences Group, Inc.
- 2026-03-19 20:05 EST — [SELLAS Life Sciences Reports Full Year 2025 Financial Results and Provides Corporate Update](https://biopharmsignal.com/news/SLS/sellas-life-sciences-reports-full-year-2025-financial-results-and-provides-corporate-update) — Source: SELLAS Life Sciences Group, Inc.
- 2026-03-17 20:30 EST — [SELLAS Life Sciences to Present Preclinical Data Highlighting Potent Activity of SLS009 in AML at the 2026 AACR Conference](https://biopharmsignal.com/news/SLS/sellas-life-sciences-to-present-preclinical-data-highlighting-potent-activity-of-sls009-in-aml-at-the-2026-aacr-conference) — Source: SELLAS Life Sciences Group, Inc.